Patients with devastating illnesses demonstrate incredible courage in battling their disease. Innovative cell and gene therapies (CGTs), built on decades of research, are changing the lives of those who suffer from conditions ranging from cancer to sickle cell disease to neurologic diseases. Although hailed for their promise and recognized for benefits that will exceed the costs, the high prices of CGTs ($300 thousand to $4 million per dose) leave these therapies out of reach for many. This accessibility problem will only be solved if academia, industry, investors, funders, regulators, and advocacy groups work together to put CGT breakthroughs in the hands of all who stand to benefit.

中文翻译：

---

细胞和基因治疗的可及性


患有严重疾病的患者在与疾病作斗争时表现出了令人难以置信的勇气。基于数十年研究的创新细胞和基因疗法 (CGT) 正在改变那些患有癌症、镰状细胞病和神经系统疾病等疾病的人们的生活。尽管 CGT 因其承诺而受到欢呼并因其超过成本的效益而受到认可，但 CGT 的高价格（每剂 30 万至 400 万美元）使这些疗法对许多人来说遥不可及。只有学术界、工业界、投资者、资助者、监管机构和倡导团体共同努力，将资本利得税的突破性成果交到所有受益者手中，这个可及性问题才能得到解决。